For patients who already have established atherosclerotic disease a prior heart attack, ischaemic stroke, or symptomatic peripheral arterial disease and who carry excess weight, the case for adding semaglutide to secondary prevention is now established. The European and American diabetes guidelines already say so in type 2 diabetes. SELECT pushes the same logic into patients without diabetes. The JACC meta-analysis suggests the benefit travels: with or without diabetes, with or without obesity, with or without chronic kidney disease. A few things the data do not yet say
The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP-1/GIP receptor agonist (BGM0504) in healthy volunteers: a dose-escalation phase I study
NexLife addresses these gaps by meeting all six v3.0 pillars flat $145/mo dose-independent pricing across the full 0.252.4 mg semaglutide titration, named 503A & 503B partner pharmacies, included labs, MD/DO supervision at every titration step, and pre-Rx written regulatory disclosure (compounded semaglutide is not FDA-approved and is not the same as Ozempic, Wegovy, or Rybelsus)
When combined with metformin, outcomes may improve further in selected patients